Afinitor 2.5 mg Compresse स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

afinitor 2.5 mg compresse

novartis pharma schweiz ag - everolimusum - compresse - everolimusum 2.5 mg, lactosum 71.875 mg, crospovidonum, hypromellosum, lactosum monohydricum 2.45 mg, magnesio stearas, e 321, pro compresso. - in combinazione con exemestane nelle donne in postmenopausa con carcinoma, hormonrezeptor positivo, her 2 negativo di cancro al seno dopo l'insuccesso di anastrozolo letrozolo o / a economie avanzate, progredienten, bene o moderatamente differenziati tumori neuroendocrini pancreatici origine / avanzate, ben differenziato (g1 o g2), non-funzionale, tumori neuroendocrini gastrointestinali o polmonari di origine con una clinicamente rilevanti progressione tumorale / con carcinoma renale metastatico, dopo fallimento di sunitinib o sorafenib - biotechnologika

Stivarga 40 mg Compresse rivestite con film स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

stivarga 40 mg compresse rivestite con film

bayer (schweiz) ag - regorafenibum - compresse rivestite con film - regorafenibum 40 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 14.01 mg, magnesii stearas, povidonum, silica colloidalis anhydrica, Überzug: lecithinum ex soja, macrogolum 3350, poly(alcohol vinylicus), talcum, e 172 (rubrum), e 172 (flavum), e 171, pro compresso obducto. - metastasiertes cancro colorettale, gastrointestinali, tumori stromali possono, carcinoma epatocellulare - synthetika

Xtandi 40 mg Capsule molli स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

xtandi 40 mg capsule molli

astellas pharma ag - enzalutamidum - capsule molli - enzalutamidum 40 mg, antiox.: e 320, e 321, excipiens per la capsula. - prostatico - synthetika

Xermelo यूरोपीय संघ - इतालवी - EMA (European Medicines Agency)

xermelo

serb sas - telotristat etiprate - carcinoid tumor; neuroendocrine tumors - altri prodotti per il tratto alimentare e il metabolismo - xermelo è indicato per il trattamento della diarrea da sindrome carcinoide in combinazione con la terapia con analoghi della somatostatina (ssa) negli adulti non adeguatamente controllati dalla terapia con ssa.

Xermelo 250 mg Compresse rivestite con film स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

xermelo 250 mg compresse rivestite con film

future health pharma gmbh - ethylis telotristatas - compresse rivestite con film - ethylis telotristatas 250 mg ut telotristati etipras 327.9 mg corresp. telotristatum 237.80 mg, lactosum 167.91 mg, hydroxypropylcellulosum, carmellosum natricum conexum, natrium 4.54 mg, magnesii stearas, silica colloidalis, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, pro compresso obducto. - tumore carcinoide di sindrome condizionale diarrea - synthetika

Xtandi 40 mg Compresse rivestite con film स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

xtandi 40 mg compresse rivestite con film

astellas pharma ag - enzalutamidum - compresse rivestite con film - enzalutamidum 40 mg, hypromellosi acetas succinas, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 3 mg, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - prostatico - synthetika

Xtandi 80 mg Compresse rivestite con film स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

xtandi 80 mg compresse rivestite con film

astellas pharma ag - enzalutamidum - compresse rivestite con film - enzalutamidum 80 mg, hypromellosi acetas succinas, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 6 mg, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - prostatico - synthetika

Opdivo यूरोपीय संघ - इतालवी - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - agenti antineoplastici - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Kisplyx यूरोपीय संघ - इतालवी - EMA (European Medicines Agency)

kisplyx

eisai gmbh - lenvatinib mesilato - carcinoma, cellule renali - agenti antineoplastici - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.